Conference Coverage

Checkpoint inhibition less toxic than antiangiogenic therapy in NSCLC

Publish date: March 30, 2018

 

REPORTING FROM THE NCCN ANNUAL CONFERENCE


This study was supported by the China Medical University Beigang Hospital.

SOURCE: Hsu C et al. NCCN poster 13

Pages

Recommended Reading

Radiation exposure in MICU may exceed recommended limit
MDedge Hematology and Oncology
The T-cell repertoire in NSCLC: Therapeutic implications
MDedge Hematology and Oncology
Imfinzi approved for stage III unresectable NSCLC
MDedge Hematology and Oncology
Hospitalizations for fracture in patients with metastatic disease: primary source lesions in the United States
MDedge Hematology and Oncology
Radiation offers no survival benefit in early lung cancer with positive margins
MDedge Hematology and Oncology
Fruquintinib promising agent for advanced NSCLC
MDedge Hematology and Oncology
FDA wants data on role of flavored tobacco products in youth initiation
MDedge Hematology and Oncology
Lower socioeconomic status linked with poor NSCLC prognosis in those with pretreatment weight loss
MDedge Hematology and Oncology
CBC data can predict immunotherapy responses in NSCLC
MDedge Hematology and Oncology
Nivolumab helps some with advanced NSCLC reach 5-year mark
MDedge Hematology and Oncology